Etude de faisabilité de l'embolisation de l'artère éthmoïdale externe dans le traitement de l'hématome progressif de l'éthmoïde chez le cheval

LYON1-BU Santé (693882101) / SudocMARCY L'ETOILE-Ec.Nat.Vétéri (691272301) / SudocSudocFranceF

The porifera <i>Hymeniacidon perlevis</i> (Montagu, 1818) as a bioindicator for water quality monitoring

International audienceBecause sponges are promising bioindicators, we present here a multispecies comparison of the bioconcentration capacity for copper, zinc and the hydrocarbon fluoranthene. The spatial distribution of sponge populations was studied in 17 areas in intertidal zones on the Lower Normandy coast (France) to determine the most common species with the highest bioaccumulation capacity. Results are compared with published data on blue mussels Mytilus edulis from the Réseau d'Observation de la Contamination Chimique biomonitoring network. A total of 720 sponge samples were collected to assess species richness. Samples were analysed for metal concentrations by flame-mode atomic absorption spectrometry. Analyses of polycyclic aromatic hydrocarbon were sub-contracted. Species richness varies according to the water mass concerned. The most common species in the study area showing the highest bioconcentration in its soft tissues is Hymeniacidon perlevis, which contains about 20 times the zinc, 44 times the copper and 16 times the fluoranthene levels found in mussels. The variability of contaminant concentrations in H. perlevis is also systematically higher than those in mussels. The results obtained for this sponge closely reflect the heterogeneous distribution of contaminants. This study demonstrates that H. perlevis has a much higher capacity to accumulate in situ contaminants than the blue mussel M. edulis. H. perlevis meets all the requirements of a good bioindicator suitable for use in an integrated monitoring programme. In the near future, controlled cultivation of H. perlevis will allow us to produce sufficient quantities of this species to carry out ecotoxicological tests and in situ biomonitoring by caging

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

International audienceObjectives: To establish recommendations on immunization for patients with multiple sclerosis (MS).Background: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.Methods: The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.Results: Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.Conclusion: Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS